UnitedHealthcare GLP-1 Coverage in Washington — 2026 Guide

UnitedHealthcare is one of the largest national health insurers, covering millions of Washington members through employer-sponsored plans, marketplace policies, and Medicare Advantage. Unlike regional carriers such as Premera or Regence, UHC manages its GLP-1 pharmacy benefit through OptumRx — their in-house pharmacy benefit manager. This means PA criteria, formulary placement, and cost-sharing rules all flow through OptumRx, not through UHC's medical team directly.

One important rule every UHC member must understand: UHC explicitly excludes compounded GLP-1 medications — semaglutide and tirzepatide — from coverage, classifying them as experimental and investigational. Only FDA-approved, brand-name GLP-1 medications filled at a standard retail pharmacy count toward your UHC pharmacy benefit. Compounded versions are a cash-pay option only and will not apply toward your deductible or out-of-pocket maximum under UHC.

UHC GLP-1 Coverage at a Glance

UHC coverage varies by indication, plan type, and employer benefit elections. Here is a summary of how OptumRx currently handles each major GLP-1 indication for Washington members:

The BMI Threshold Quirk: Zepbound May Be Easier to Get Than Wegovy

Here is a counterintuitive but real feature of some UHC plan designs: certain plans set a BMI threshold of ≥40 for Wegovy specifically — substantially higher than the FDA-approved criterion of BMI ≥30 and higher than the standard PA requirement used by most carriers. However, those same plans may maintain a lower BMI threshold for Zepbound, as low as ≥30 or ≥27 with a comorbidity.

This means a UHC member with a BMI of 33 might be denied Wegovy under their plan's specific benefit design — but could be approved for Zepbound under the same plan, because the two medications have different threshold criteria in the plan document. If you've been told you don't qualify for Wegovy, it is worth explicitly asking whether Zepbound has a different qualification threshold on your specific UHC plan. Both medications should be evaluated separately.

12-Month Approval Windows: More Patient-Friendly Than Most Carriers

UHC approves GLP-1 prior authorizations for 12 months at a time through OptumRx. Annual renewal requires updated labs demonstrating continued clinical appropriateness — typically weight, BMI, HbA1c if applicable, and a brief clinical narrative confirming ongoing response to therapy.

This 12-month window is more patient-friendly than carriers with shorter initial approval periods. Cigna, for comparison, uses an 8-month initial approval window for some indications. The longer UHC window reduces the administrative burden on both the patient and the prescribing provider, with only one renewal cycle per year rather than multiple shorter cycles.

The CV Risk Pathway at UHC

Following the SELECT trial data showing that semaglutide (Wegovy) reduces major adverse cardiovascular events in patients with established cardiovascular disease, UHC covers Wegovy under a cardiovascular indication that operates independently of the weight management benefit. Requirements are established CVD (prior heart attack, stroke, peripheral arterial disease, or other qualifying cardiac event) plus BMI ≥27.

The PA for the CV indication is submitted separately from any anti-obesity medication benefit and does not require that the employer have purchased an AOM rider. Patients with established CVD and a BMI above 27 should explore this pathway before assuming they need an AOM benefit to access Wegovy.

Zepbound for OSA at UHC

UHC has built a specific OSA pathway into their GLP-1 coverage framework. Members with moderate-to-severe obstructive sleep apnea — defined as an Apnea-Hypopnea Index (AHI) ≥15 on a qualifying sleep study — plus a BMI ≥30 qualify for Zepbound coverage under this pathway. Like the CV risk pathway, the OSA pathway does not require the weight management benefit to be elected by the employer.

This is a significant coverage opportunity for UHC members who lack an AOM benefit but have sleep apnea. The clinical documentation required includes the sleep study report showing AHI ≥15, confirmation of obstructive (not central) sleep apnea, and a current BMI calculation. Revive can coordinate the PA documentation if the OSA diagnosis is already established; patients without a sleep study should get one prior to pursuing this pathway.

UHC's Compounded GLP-1 Exclusion: What It Means for You

UHC's exclusion of compounded semaglutide and tirzepatide is a standing clinical coverage policy — these medications are classified as experimental and investigational under the OptumRx pharmacy benefit. This means if you have UHC, the compounded versions will never apply toward your deductible, out-of-pocket maximum, or co-insurance.

The practical implication: if you have a UHC plan that covers GLP-1s under any indication, you want an FDA-approved brand-name product filled at a standard retail pharmacy. Compounded GLP-1s remain a cash-pay alternative available regardless of insurance, but using them means leaving your UHC benefit on the table if you otherwise qualify.

Estimated Patient Costs (Through OptumRx)

Common Questions From UHC Members

Does my UHC plan cover GLP-1s for weight loss?

It depends on whether your employer opted into the weight management benefit when they configured your UHC plan. The fastest way to find out is to call OptumRx directly at the number on the back of your UHC card and ask specifically about anti-obesity medication (AOM) coverage. You can also check through the UHC member portal under your pharmacy benefit details. If your employer is large enough, your HR or benefits team can tell you whether AOM coverage was elected.

What's the difference between UHC's BMI requirements for Wegovy vs. Zepbound?

Some UHC plans set a BMI ≥40 threshold for Wegovy specifically — much higher than FDA labeling — while the same plans may require only BMI ≥30 for Zepbound. If you have a BMI between 30 and 40 and were told you don't qualify for Wegovy, it's worth asking your provider to check Zepbound eligibility separately. The two medications are evaluated against different criteria in some UHC plan documents.

Does UHC cover compounded semaglutide?

No — UHC excludes compounded GLP-1 medications (semaglutide and tirzepatide) from coverage under the OptumRx pharmacy benefit, classifying them as experimental and investigational. Only FDA-approved brand medications (Ozempic, Wegovy, Mounjaro, Zepbound) filled at a standard retail pharmacy are covered. Compounded GLP-1s are a cash-pay option only and won't count toward your deductible or OOP max under UHC.

Related GLP-1 Coverage Guides

• Complete GLP-1 Insurance Coverage Guide — Washington 2026
• Premera Blue Cross GLP-1 Coverage in Washington — 2026 Guide
• Regence GLP-1 Coverage in Washington — 2026 Guide
• Kaiser Permanente GLP-1 Coverage in Washington — 2026 Guide
• Aetna GLP-1 Coverage in Washington — 2026 Guide